Clinical trial · Interventional
Radiation Therapy in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Grade II or Grade III Meningioma
Adjuvant Postoperative High-Dose Radiotherapy for Atypical and Malignant Meningioma: a Phase-II and Observation Study
NCT00626730CI-TRIAL-00049806unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving high-dose radiation therapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying radiation therapy to see how well it works in treating patients who have undergone surgery for newly diagnosed grade II or grade III meningioma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain and Central Nervous System Tumors | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| adjuvant therapy | Procedure | — | UNRESOLVED |
| radiation therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Progression-free survival
Secondary outcomes (3)
- measure
- Adverse events as assessed by NCI CTCAE v3.0
- measure
- Mini-mental status exam
- measure
- Overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically confirmed newly diagnosed meningioma, including the following subtypes:
* Atypical WHO grade II meningioma greater than or equal to 4 mitosis per high-power field \[HPF\] or the presence of at least 3 of the following variables:
* Cellularity
* Architectural sheeting (i.e., patternless pattern)
* Macronuclei cell formation
* Small cell formation
* Malignant WHO grade III meningioma
* All locations allowed except for optic nerve sheets tumors
* Complete or subtotal resection as assessed by the surgeon after verification with a postoperative MRI and according to Simpson guidelines
* No neurofibromatosis type 2 (NF-2)
PATIENT CHARACTERISTICS:
* WHO performance status 0-2
* Not pregnant or nursing
* Fertile patients must use effective contraception during study therapy
* May be registered on this trial only once
* No clinical evidence of second malignancies except carcinoma in situ of the cervix or basocellular carcinoma
* No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
PRIOR CONCURRENT THERAPY:
* No prior radiotherapy to the brain or meninges interfering with the protocol treatment planReferences
Publications (0)
Data not yet available
No reference posted for this study.